CN109588698A - A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method - Google Patents
A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method Download PDFInfo
- Publication number
- CN109588698A CN109588698A CN201710918907.XA CN201710918907A CN109588698A CN 109588698 A CN109588698 A CN 109588698A CN 201710918907 A CN201710918907 A CN 201710918907A CN 109588698 A CN109588698 A CN 109588698A
- Authority
- CN
- China
- Prior art keywords
- sulforaphen
- alcoholism
- functional food
- preventing
- oral solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 27
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 27
- 235000013376 functional food Nutrition 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title description 5
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 claims abstract description 44
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 claims abstract description 44
- 239000000419 plant extract Substances 0.000 claims abstract description 10
- 229940100688 oral solution Drugs 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 6
- 235000005687 corn oil Nutrition 0.000 claims description 4
- 239000002285 corn oil Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000008157 edible vegetable oil Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 54
- 235000019441 ethanol Nutrition 0.000 abstract description 36
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004556 brain Anatomy 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 102000016938 Catalase Human genes 0.000 abstract description 4
- 108010053835 Catalase Proteins 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 239000000178 monomer Substances 0.000 abstract description 3
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 230000002787 reinforcement Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000002265 prevention Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 206010003084 Areflexia Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010947 Coordination abnormal Diseases 0.000 description 2
- 206010016825 Flushing Diseases 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 208000016290 incoordination Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 101000957377 Rattus norvegicus Cytochrome P450 2B2 Proteins 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 108010076830 Thionins Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- QJIRKQIIUUYESB-UHFFFAOYSA-N [O].CC=O Chemical compound [O].CC=O QJIRKQIIUUYESB-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses sulforaphen or the plant extracts containing sulforaphen in the technical solution for preparing the application in functional food or drug for preventing and treating mental disorder induced by alcoholism.The research of the invention finds that sulforaphen, to generate the ability that powerful ethanol conversion is acetaldehyde in intracerebral, can mitigate ethyl alcohol to the depression effect of brain by activation Nrf2 transcriptional activity come the expression of catalase in reinforcement.Therefore, sulforaphen can be used for preparing drug and functional food for preventing or treating alcoholism.Sulforaphen can be chemical monomer, and the plant extracts containing sulforaphen can also be used.
Description
Technical field
The invention belongs to functional food and field of pharmaceutical technology, it is related to preventing and treating the functionality of mental disorder induced by alcoholism
Food and drug and preparation method thereof.
Background technique
China is big country of drinking.Alcoholism is commonly called as drunk, refers to that patient drinks the body machine that a large amount of alcohol (ethyl alcohol) occur afterwards
Energy abnormality injures most serious to nervous system and liver.Medically it is divided into acute poisoning and two kinds of slow poisoning, Qian Zhe
Injury is brought to patient in short time, it might even be possible to breathing, heartbeat inhibition be made to lead to death.The latter brings cumulative bad to hurt to patient
Evil, such as alcohol dependence, phrenoblabia, alcoholic cirrhosis and induction cancer.Insanity state can occur for patient with slight symptoms, such as talk about
More, irritability, flushed face or it is pale, eye is congested, increased heart rate, giddy, headache etc..There is instability of gait, moves in patient with severe symptoms
Make ambiguous clumsiness, speech, incoherent, blurred vision and ghost image, and can have Nausea and vomiting etc., and then be in lethargic state, complexion
Pale, cyanotic lips, skin is clammy, temperature decline, hypopnea, pupil expand.Serious person falls into deep coma, blood pressure declines,
Slow respiration, increased heart rate, until failure is dead.Alcoholism incidence is very high, is serious public health event.According to system
Meter China dies of cerebral hemorrhage caused by alcoholism just every year 110,000 people.At present clinically for alcoholism mainly with right
Based on disease treatment, by removing poisonous substance (emetic, gastric lavage, catharsis), fluid infusion, furosemide and Allylnoroxymorphone antidotal therapy, but for alcohol
The prevention of poisoning also lacks effective means.
It is most of to be developed for the injury of liver caused by alcohol at present in the product of the prevention and treatment alcoholism of exploitation
Liver-protecting product, injury dirty for nervous system caused by alcohol, especially mental disorder induced by alcoholism, the product lacked.
Effect of the alcohol for nervous system, show it is first excited after inhibit, the characteristics of Small Dose Excitement large dosage inhibits.It inhibits effect
It should mainly be mediated by the prototype form ethyl alcohol of alcohol, the effects such as nervous excitation effect and flushed face, palpitating speed are by wine
The metabolite acetaldehyde of essence mediates.Alcohol is much to activate GABA system pair with excessive ethyl alcohol itself to the injury of nervous system
Comprehensive inhibit of brain and realize.
The dosis toxica and lethal dose of alcohol vary with each individual closely related with the ability of human body conversion metabolism alcohol.Alcohol is inhaled
Metabolism after receipts in vivo is broadly divided into three steps: first passing around the metabolic system of several complexity, comprising: alcohol dehydrogenase, cell
Tri- enzymatic oxidation systems of cytochrome p 450 E and catalase, are changed into acetaldehyde for ethyl alcohol；Again through acetaldehyde-dehydrogenase enzymatic acetaldehyde oxygen
Metaplasia is at acetic acid；Last acetic acid is carbon dioxide and water by breathing discharge or metabolic breakdown.Wherein, ethyl alcohol is changed into acetaldehyde
Enzyme system in, alcohol dehydrogenase is the main enzyme system that alcohol oxidation is metabolized to acetaldehyde in liver, and catalase is wine in brain
Smart oxidative metabolism at acetaldehyde main enzyme system.Alcohol in brain can metabolic transformation be in time acetaldehyde, can significantly mitigate ethyl alcohol pair
The depression effect of nervous system slows down and prevents the alcoholism of nervous system.
Dietetic treatment has been proved by more and more medical researches in the important function treated and prevented in a variety of diseases.Wine
The early prevention of essence poisoning often has bigger meaning than treatment.Sulforaphen (chemical name: 1- isothiocyanic acid -4- mesyl
Butane), it is common food-borne antioxygen that content is relatively abundant in the crucifers such as broccoli, cabbage mustard, north circle carrot
Agent has great edible value.Studies have shown that sulforaphen has low toxicity and preferable safety.Therefore, it originally grinds
Study carefully and provides a kind of functional food of prevention and treatment mental disorder induced by alcoholism based on sulforaphen.
Summary of the invention
The task of the present invention is provide a kind of functional food for preventing and treating mental disorder induced by alcoholism and drug and its system
Method.
The present invention is prepared for a kind of functional food and medicine for preventing and treating alcoholism for the technical problem in alcoholism
Product.Inventor's the study found that sulforaphen can by activation Nrf2 transcriptional activity come the expression of catalase in reinforcement, from
And the ability that powerful ethanol conversion is acetaldehyde is generated in intracerebral, mitigate ethyl alcohol to the depression effect of brain.Therefore, sulforaphen
It can be used for preparing drug and functional food prevention or treatment alcoholism.Sulforaphen can be chemical monomer, can also be used and contains
The plant extracts of sulforaphen.
Realize the technical scheme is that
The present invention provides sulforaphen or the plant extracts containing sulforaphen is smart for preventing and treating alcoholic-toxic in preparation
The functional food of refreshing obstacle or the technical solution of the application in drug.
The functional food or drug of prevention and treatment mental disorder induced by alcoholism provided by the invention, containing following component a or
The other ingredients for allowing to add in ingredient b and functional food or in pharmaceutics:
A. sulforaphen；
B. containing the plant extracts of sulforaphen.
Sulforaphen concentration can be in the range of 0.1-1mg/ml.
Provided by the present invention for preventing and treating the oral solution of mental disorder induced by alcoholism, by sulforaphen or functional food
Acceptable solvent composition, the concentration range of sulforaphen is 0.1-1mg/ml, and surplus is solvent, and the solvent is edible oil,
Corn oil can specifically be used.The pH value of oral solution can be adjusted to 5.5-6.0 by citric acid and sodium citrate, can be in oral solution
Suitable sucrose is added.Make a concrete scheme to realize the present invention, can also be with the oral solution that aforementioned present invention provides
Soft capsule is made in content.
A technical solution of the invention is to be configured to corn oil using sulforaphen as main component, be used to prepare
The drug and functional food of prevention or treatment alcoholism.Implementation of the invention can be used alone, and acceptable excipients can also be added
Agent uses after other dosage forms are made.It is recommended that the dosage form taken is soft capsule.Suitable drug release can be used in this functional food
System, or shared with other function product, to obtain more favorable effect.This functional food also can be used rich in radish
The plant extracts of thionin, such as Caulis et Folium Brassicae capitatae are prepared.The present invention, can be with using sulforaphen as main active
It is the chemical monomer of sulforaphen, can also be mouth made by the composition or plant extracts containing sulforaphen as effective component
Take liquid.Administration route is oral.Pharmaceutical composition containing this effective component can use suitable drug delivery system to obtain
More favorable effect.The sleep of mouse caused by ethyl alcohol, temperature decline peace can be significantly inhibited using functional food of the invention
Weigh Disability, and the present invention is for the stupor of depth caused by clinically alcoholism, temperature decline, instability of gait, clumsy in one's movement
Etc. symptoms have significant prevention effect.Sulforaphen can be used to prepare the drug and functional food of prevention and treatment alcoholism.
Detailed description of the invention
Fig. 1 is the experimental result picture of embodiment 2.
Fig. 2 is the experimental result picture of embodiment 3.
Fig. 3 is the experimental result picture of embodiment 4.
Specific embodiment
Feature available reference following embodiment of the invention is described further, but these embodiments are not considered as appointing
What is for limitation range of the invention.
The preparation of the sulforaphen oral solution provided by the invention of embodiment 1
Formula: corn oil 1000ml is added in sulforaphen 500mg.Stirring and dissolving.Add sucrose appropriate.Add citric acid and citron
Sour sodium adjusts PH to 5.7.It stirs evenly, is dispensed after filtering, cryo-conservation (4 degree).Recommended doses: adult 10-20ml/ days.
The oral solution of the present invention of embodiment 2 significantly postpones mouse time for falling asleep caused by ethyl alcohol
10-12 weeks mouse, 25-30g are injected intraperitoneally sulforaphen 5mg/kg continuous 5 days, detection acute alcohol administration in the 6th day
The righting reflex loss of induction: 20%v/v alcoholic solution is injected intraperitoneally by 4.0g/kg concentration in mouse, disappears to mouse righting reflex
After mistake, mouse is placed in V-type device, sleeping time of the total duration of mouse righting reflex loss as mouse is recorded, as a result demonstrate,proves
Real sulforaphen can obviously reduce alcohol-induced mice sleep duration.Control: 43.37 ± 5.264 minutes；Sulforaphen: 31.00
± 5.091 minutes.N=10.Experimental result is referring to attached drawing 1.
The oral solution of the present invention of embodiment 3 significantly inhibits the decline of mouse anus temperature caused by ethyl alcohol
10-12 weeks mouse, 25-30g are injected intraperitoneally sulforaphen 5mg/kg continuous 5 days, detection acute alcohol administration in the 6th day
The core temperature of induction reduces.Hour basal body temperature is detected using anus temperature meter, mouse is injected intraperitoneally by 3.0g/kg concentration later
20%v/v alcoholic solution is measured respectively to the core body of mouse after 30 minutes after alcohol, 60 minutes, 90 minutes and 120 minutes
Temperature takes the average value of this four body temperature, calculates mouse temperature and declines absolute value, discovery sulforaphen can be relieved alcohol induction
Core temperature reduce.Control: 2.269 ± 0.1618 degrees Celsius；Sulforaphen: 1.647 ± 0.05718 degrees Celsius.N=10.It is real
Result is tested referring to attached drawing 2.
The oral solution of the present invention of embodiment 4 significantly inhibits the forfeiture of mouse balanced capacity caused by ethyl alcohol
10-12 weeks mouse, 25-30g are injected intraperitoneally sulforaphen 5mg/kg continuous 5 days, detection acute alcohol administration in the 6th day
The incoordination of induction.Acceleration mode, minimum speed 8rpm, maximum speed 40rpm, Shi Changwei are set by runner
5min.The incubation period fallen from runner under mouse normal condition is recorded first, is injected intraperitoneally later by 1.75g/kg concentration
20%v/v alcoholic solution records the incubation period fallen to mouse after alcohol 30min from runner, and it is exhausted to calculate incubation period difference twice
To value, to assess alcohol induction incoordination, incubation period phase absolute value of the difference is bigger before and after ethanol postincubation, illustrates caused by alcohol
Balanced capacity is lost more serious.It was found that sulforaphen significantly reduces the change of incubation period caused by alcohol, alcohol can be obviously improved and lured
The balanced capacity led is lost.Control: 27.35 ± 2.327 minutes；Sulforaphen: 7.050 ± 1.582 minutes.N=10.Experiment knot
Fruit is referring to attached drawing 3.
Claims (10)
1. sulforaphen or the plant extracts containing sulforaphen are preparing the functionality for preventing and treating mental disorder induced by alcoholism
Application in food or drug.
2. a kind of functional food or drug for preventing and treating mental disorder induced by alcoholism, contains following component a or ingredient b and function
The other ingredients for allowing to add in energy property food or in pharmaceutics:
A. sulforaphen；
B. containing the plant extracts of sulforaphen.
3. functional food according to claim 2, which is characterized in that the plant extracts containing sulforaphen
It is Caulis et Folium Brassicae capitatae.
4. functional food according to claim 2 or 3, which is characterized in that sulforaphen concentration range is 0.1-1mg/
ml。
5. it is a kind of for preventing and treating the oral solution of mental disorder induced by alcoholism, it is acceptable molten by sulforaphen or functional food
The concentration range of agent composition, sulforaphen is 0.1-1mg/ml, and surplus is solvent.
6. oral solution according to claim 5, which is characterized in that the solvent is edible oil.
7. oral solution according to claim 5, which is characterized in that the solvent is corn oil.
8. according to oral solution described in claim 5,6 or 7, which is characterized in that the pH value of the oral solution is via citric acid and Chinese holly
Rafter acid sodium is adjusted to 5.5-6.0.
9. according to oral solution described in claim 5,6,7 or 8, which is characterized in that joined sucrose in the oral solution.
10. a kind of for preventing and treating the functional food or pharmaceutical preparation of mental disorder induced by alcoholism, which is characterized in that it be with
Oral solution described in any one of claim 5 to 9 is the soft capsule of content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710918907.XA CN109588698A (en) | 2017-09-30 | 2017-09-30 | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710918907.XA CN109588698A (en) | 2017-09-30 | 2017-09-30 | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109588698A true CN109588698A (en) | 2019-04-09 |
Family
ID=65956730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710918907.XA Pending CN109588698A (en) | 2017-09-30 | 2017-09-30 | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109588698A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021048806A (en) * | 2019-09-26 | 2021-04-01 | カゴメ株式会社 | Melatonin production promoter and sleep quality improver |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208079A (en) * | 2005-04-29 | 2008-06-25 | 约翰斯霍普金斯大学 | Methods of suppressing UV light-induced skin carcinogenesis |
| CN102898341A (en) * | 2012-10-26 | 2013-01-30 | 贵州大学 | Extracting and purifying method of high-purity sulforaphane |
| US20160166626A1 (en) * | 2014-04-23 | 2016-06-16 | Lifevantage Corporation | Topical compositions and methods for reducing oxidative stress |
| CN106344626A (en) * | 2016-08-24 | 2017-01-25 | 徐金蝶 | Preparation method of sulforaphane soft capsules |
-
2017
- 2017-09-30 CN CN201710918907.XA patent/CN109588698A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208079A (en) * | 2005-04-29 | 2008-06-25 | 约翰斯霍普金斯大学 | Methods of suppressing UV light-induced skin carcinogenesis |
| CN102898341A (en) * | 2012-10-26 | 2013-01-30 | 贵州大学 | Extracting and purifying method of high-purity sulforaphane |
| US20160166626A1 (en) * | 2014-04-23 | 2016-06-16 | Lifevantage Corporation | Topical compositions and methods for reducing oxidative stress |
| CN106344626A (en) * | 2016-08-24 | 2017-01-25 | 徐金蝶 | Preparation method of sulforaphane soft capsules |
Non-Patent Citations (2)
| Title |
|---|
| CHEN,X，等: "Sulforaphane protects against ethanol-induced oxidative stress and apoptosis in neural crest cells by the induction of Nrf2-mediated antioxidant response", 《BRITISH JOURNAL OF PHARMACOLOGY》 * |
| JUAN CARLOS LEDESMA，等: "Alpha-lipoic acid, a scavenging agent for H2O2, reduces", 《PSYCHOPHARMACOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021048806A (en) * | 2019-09-26 | 2021-04-01 | カゴメ株式会社 | Melatonin production promoter and sleep quality improver |
| JP7499013B2 (en) | 2019-09-26 | 2024-06-13 | カゴメ株式会社 | Melatonin production promoter and sleep quality improver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006305309A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| JP2013532666A (en) | Anti-fatigue composition, its formulation and application | |
| CN108012527A (en) | Benzimidizole derivatives are used for the purposes of Control of Nocturnal Gastric Acid Breakthrough | |
| Montero et al. | Intranasal midazolam for the emergency management of hypercyanotic spells in tetralogy of Fallot | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| Haji et al. | Increased feline cerebral blood flow induced by dehydroevodiamine hydrochloride from Evodia rutaecarpa | |
| CN105311081A (en) | Application of Shanhaidan chrysanthemum indicum injection in aerosol inhalation, spray bottle aerial fog and rectal administration and method | |
| CN109588698A (en) | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method | |
| CN110522748B (en) | Application of ginkgolide in preparing medicament and health-care product for preventing and/or treating tremors | |
| CN102716119A (en) | Novel application of (-)-epigallocatechin gallate in treatment of depression | |
| CN103655925B (en) | A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN103877074B (en) | Application of 5,6,7,8- trihydroxy-8-methoxyflavone in preparing anti-hypoxic drug | |
| CN105541838B (en) | A kind of pharmaceutical composition for treating kidney stone | |
| CN100431532C (en) | Breviscapine and borneol constituted composite injection formulation and preparation method thereof | |
| JP2007277207A (en) | Preparation for internal use | |
| EP4209135A1 (en) | Composition for removing hangover and improving liver function | |
| JP4462401B2 (en) | Anti-snoring agent | |
| CN104147173B (en) | A kind of Chinese medicine composition treating acute alcoholism | |
| JP7455293B2 (en) | Composition for improving sequelae after stroke | |
| CN104138557A (en) | Chinese herbal medicine compound preparation for preventing and treating senile dementia | |
| CN107157970A (en) | Purposes of the aloe-emodin in prevention and treatment myocardial ischemia and antiarrhythmic medicament is prepared | |
| Cholewa et al. | Effects of naloxone on ethanol-induced coma | |
| JP2007191426A (en) | Anti-overwork composition | |
| CN106265674A (en) | Tetramethyluric acid prevention and the application for the treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190409 |
|
| RJ01 | Rejection of invention patent application after publication |